Intech Biopharm Corporation (TPEX:6461)

Market Cap	2.80B
Revenue (ttm)	32.67M
Net Income (ttm)	-381.66M
Shares Out	137.94M
EPS (ttm)	-2.78
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,354,754
Average Volume	342,412
Open	21.55
Previous Close	21.75
Day's Range	20.25 - 21.55
52-Week Range	16.50 - 34.60
Beta	-0.12
RSI	61.78
Earnings Date	Aug 10, 2025

About Intech Biopharm

Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names. Intech Biopharm Corporation was founded in 2010 and is headquartered in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 90
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6461

Financial Performance

In 2024, Intech Biopharm's revenue was 39.78 million, an increase of 53.90% compared to the previous year's 25.85 million. Losses were -368.21 million, 8.94% more than in 2023.